152 related articles for article (PubMed ID: 11773161)
1. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
Agarwala SS; Glaspy J; O'Day SJ; Mitchell M; Gutheil J; Whitman E; Gonzalez R; Hersh E; Feun L; Belt R; Meyskens F; Hellstrand K; Wood D; Kirkwood JM; Gehlsen KR; Naredi P
J Clin Oncol; 2002 Jan; 20(1):125-33. PubMed ID: 11773161
[TBL] [Abstract][Full Text] [Related]
2. The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma.
Beusterien KM; Ackerman SJ; Plante K; Glaspy J; Naredi P; Wood D; Gehlsen K; Agarwala SS
Support Care Cancer; 2003 May; 11(5):304-12. PubMed ID: 12720074
[TBL] [Abstract][Full Text] [Related]
3. Are all hypotheses generated before data analysis prospective?
Urba WJ; Alvord WG
J Clin Oncol; 2002 Mar; 20(6):1431-3. PubMed ID: 11896085
[No Abstract] [Full Text] [Related]
4. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
6. Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Lindnér P; Rizell M; Mattsson J; Hellstrand K; Naredi P
Anticancer Res; 2004; 24(3b):1837-42. PubMed ID: 15274364
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Schmidt H; Larsen S; Bastholt L; Fode K; Rytter C; Von Der Maase H
Ann Oncol; 2002 Dec; 13(12):1919-24. PubMed ID: 12453861
[TBL] [Abstract][Full Text] [Related]
8. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
9. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
10. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
Ridolfi R; Chiarion-Sileni V; Guida M; Romanini A; Labianca R; Freschi A; Lo Re G; Nortilli R; Brugnara S; Vitali P; Nanni O;
J Clin Oncol; 2002 Mar; 20(6):1600-7. PubMed ID: 11896110
[TBL] [Abstract][Full Text] [Related]
11. Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis.
O'Day SJ; Agarwala SS; Naredi P; Kass CL; Gehlsen KR; Glaspy J
Melanoma Res; 2003 Jun; 13(3):307-11. PubMed ID: 12777988
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.
Andrès P; Cupissol D; Guillot B; Avril MF; Drèno B
Eur J Dermatol; 1998 Jun; 8(4):235-9. PubMed ID: 9649695
[TBL] [Abstract][Full Text] [Related]
13. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up.
Weide B; Eigentler TK; Pflugfelder A; Leiter U; Meier F; Bauer J; Schmidt D; Radny P; Pföhler C; Garbe C
Cancer Immunol Immunother; 2011 Apr; 60(4):487-93. PubMed ID: 21174093
[TBL] [Abstract][Full Text] [Related]
14. Results of a multicenter randomized study to evaluate the safety and efficacy of combined immunotherapy with interleukin-2, interferon-{alpha}2b and histamine dihydrochloride versus dacarbazine in patients with stage IV melanoma.
Middleton M; Hauschild A; Thomson D; Anderson R; Burdette-Radoux S; Gehlsen K; Hellstrand K; Naredi P
Ann Oncol; 2007 Oct; 18(10):1691-7. PubMed ID: 17709802
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
17. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
[TBL] [Abstract][Full Text] [Related]
18. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
Flaherty LE; Atkins M; Sosman J; Weiss G; Clark JI; Margolin K; Dutcher J; Gordon MS; Lotze M; Mier J; Sorokin P; Fisher RI; Appel C; Du W
J Clin Oncol; 2001 Jul; 19(13):3194-202. PubMed ID: 11432886
[TBL] [Abstract][Full Text] [Related]
19. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Chapman PB; Einhorn LH; Meyers ML; Saxman S; Destro AN; Panageas KS; Begg CB; Agarwala SS; Schuchter LM; Ernstoff MS; Houghton AN; Kirkwood JM
J Clin Oncol; 1999 Sep; 17(9):2745-51. PubMed ID: 10561349
[TBL] [Abstract][Full Text] [Related]
20. Alternating chemo-immunotherapy with temozolomide and low-dose interleukin-2 in patients with metastatic melanoma.
Masucci GV; Månsson-Brahme E; Ragnarsson-Olding B; Nilsson B; Wagenius G; Hansson J
Melanoma Res; 2006 Aug; 16(4):357-63. PubMed ID: 16845332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
